Last updated: February 20, 2026
What is the indication and formulation of NDC 59762-0050?
NDC 59762-0050 corresponds to Ubrogepant (marketed as Ubrelvy) in a 50 mg tablet form. Ubrogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine with or without aura.
Market Overview
Market Size and Growth
The global migraine treatment market was valued at approximately $4.6 billion in 2022. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.2% between 2023 and 2030, driven by increasing prevalence and awareness.
Prevalence Data
- Global migraine prevalence: 15% of the adult population.
- U.S. adult migraine sufferers: approximately 39 million.
- Market penetration of CGRP antagonists: around 20% of patients with diagnosed migraines.
Competitive Landscape
Major competitors include:
- Erenumab (Aimovig)
- Fremanezumab (Ajovy)
- Galcanezumab (Emgality)
- OnabotulinumtoxinA (Botox)
Ubrogepant faces competition primarily from oral and non-oral treatments, with the CGRP class expanding rapidly.
Regulatory Status
- FDA approval granted in 2019.
- EMA approval received in 2020.
Insurance and Reimbursement
Coverage is generally aligned with other migraine treatments, with most commercial insurers covering Ubrogepant, but with prior authorization requirements.
Price Analysis
Current Pricing
- Average Wholesale Price (AWP): approximately $80 per 50 mg tablet.
- Negotiated retail prices vary; typical cash prices hover around $50–$70 per tablet.
- Insurance copays: typically $10–$40 per tablet depending on plan.
Competitor Pricing
| Drug |
Dose |
Approximate Price per Dose |
Delivery Method |
| Ubrogepant (59762-0050) |
50 mg tablet |
$50–$70 |
Oral tablet |
| Aimovig (Erenumab) |
70 mg or 140 mg |
$575/month |
Self-injector |
| Ajovy (Fremanezumab) |
225 mg/675 mg |
$600–$700/25 mg dose |
Subcutaneous injection |
Note: Ubrogepant is priced lower per dose than injectable CGRP antagonists, targeting a different segment of migraine sufferers who prefer oral medication.
Price Projection Drivers
Factors influencing future pricing include:
- Entry of generics or biosimilars
- Market penetration of competitors
- Insurance reimbursement policies
- Patents and exclusivity status (patent expiration expected in 2027)
Price Projection Scenarios
| Scenario |
Timeline |
Price Trend |
Key Drivers |
| Conservative |
2024–2028 |
Stable, slight decline (~5%) |
Patent exclusivity, limited generic competition |
| Moderate |
2024–2028 |
Gradual decline (~10%) |
Entry of generics in late 2027 |
| Aggressive |
2024–2028 |
Faster decline (~20%) |
Early biosimilar/better competition, price pressures |
Revenue Forecasts
Assuming 1 million prescriptions annually by 2025, with an average price per tablet of $60:
| Year |
Prescriptions |
Revenue (millions USD) |
Notes |
| 2023 |
600,000 |
$36 million |
Launch year, moderate adoption |
| 2025 |
1,000,000 |
$60 million |
Market matured, competitive effects begin |
| 2028 |
1,200,000 |
$84 million |
Post-generic entry impacts pricing |
Risks to Price Stability
- Patent expiration in 2027.
- Development of oral or non-CGRP alternatives.
- Healthcare policy changes impacting drug reimbursement.
- Clinical trial results impacting demand.
Key Takeaways
- NDC 59762-0050, Ubrogepant, is a leading oral CGRP antagonist for acute migraine treatment.
- Current prices range from $50–$70 per tablet, with potential for slight decline over the next 5 years.
- Market competition includes both injectable CGRP inhibitors and emerging oral agents.
- Price erosion is likely after patent expiry, projected around 2027.
- Revenue growth will depend on market penetration, reimbursement, and competitive dynamics.
FAQs
1. What factors influence the price of NDC 59762-0050?
Market competition, patent status, insurance reimbursement policies, and generic entry.
2. How does Ubrogepant compare price-wise to injectable CGRP therapies?
It is priced lower per dose—around $50–$70—versus $575/month for Aimovig.
3. When is patent expiry expected for Ubrogepant?
Approximately 2027, after which price erosion and generic competition are anticipated.
4. What is the potential market size for Ubrogepant?
An estimated 39 million U.S. migraine sufferers, with about 20% likely to opt for CGRP antagonists.
5. How might insurance policies affect future prices?
Reimbursement restrictions and prior authorization may influence patient access and pricing pressures.
References:
- MarketWatch. (2023). Global migraine treatment market size and forecast. https://www.marketwatch.com
- FDA. (2019). Approval of Ubrogepant for migraine. https://www.fda.gov
- IQVIA. (2022). Pharmaceutical market analytics data.
- GoodRx. (2023). Ubrogepant prices and comparisons. https://www.goodrx.com
- EvaluatePharma. (2023). Pipeline and patent expiry analysis. https://www.evaluate.com
